Needham Keeps Buy on Rigel Pharmaceuticals

Analyst Mark Monane cites positive data results for the company's allergy treatment

Needham reiterated the buy rating on Rigel Pharmaceuticals (RIGL ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.